Azathioprine and anti-TNFα therapies in Crohn’s disease: a review of pharmacology, clinical efficacy and safety
- 31 January 2003
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 47 (1) , 1-10
- https://doi.org/10.1016/s1043-6618(02)00264-5
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's diseaseNature, 2001
- A frameshift mutation in NOD2 associated with susceptibility to Crohn's diseaseNature, 2001
- Prospective survey of childhood inflammatory bowel disease in the British IslesThe Lancet, 2001
- Smoking cessation and the course of Crohn's disease: An intervention studyGastroenterology, 2001
- Inflammatory bowel disease: epidemiology and management in an English general practice populationAlimentary Pharmacology & Therapeutics, 2000
- Incidence of juvenile-onset Crohn's disease in ScotlandThe Lancet, 1999
- Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.Gut, 1996
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995
- Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's diseaseGastroenterology, 1993
- The clinical pharmacology of 6-mercaptopurineEuropean Journal of Clinical Pharmacology, 1992